mesothelioma/kräkning

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 109 resultat

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND An expanded access program (EAP) provided patient access to pemetrexed prior to its commercial availability. The current report consists of US patients in the EAP who had chemotherapy naïve pleural mesothelioma. METHODS Eligible patients had a histologic or cytologic diagnosis of

A phase II study of pirarubicin in malignant pleural mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Thirty-five non-pretreated patients (29 male, six female) with malignant pleural mesothelioma, median age of 68.5 years (range, 29 to 78 years) and a median performance status of 80% (range, 60% to 100%) were treated with 70 mg/m2 Pirarubicin. The treatment was repeated every 3 to 4 weeks (median

A rare cause of dysphagia: malignant pleural mesothelioma in the posterior mediastinum.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A 69-year-old man presented to the emergency room with dysphagia and vomiting. A computed tomographic scan revealed a posterior mediastinal mass surrounding the lower portion of the esophagus. Endoscopic examination demonstrated narrowing of the lower esophagus without malignant mucosal lesions.

[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND We performed a phase-II-study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i. e., ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for

A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A total of 29 previously untreated patients with histologically proven malignant pleural mesothelioma, with an ECOG score of < or = 2 and UICC stage I-II disease, were enrolled between May 1994 and October 1996. On days 1 and 2, 18 x 10(6) IU/day of rIL-2 was administered by continuous intravenous

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mg/m2 on days 1, 3 and 5 every 3 weeks. The second trial

Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Diffuse malignant peritoneal mesotheliomas in children are uncommon, aggressive tumors with a grave prognosis. We herein report the clinical, radiologic, and pathologic findings of a 16-year-old male. The adolescent presented with a history of abdominal pain, nausea and daily, nonbilious, nonbloody

Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE The combination of chemotherapy, surgery, and radiotherapy has improved the prognosis for patients with malignant pleural mesothelioma (MPM). Intensity-modulated radiotherapy (IMRT) has allowed for an increase in dose to the pleural cavity and a reduction in radiation doses to organs at

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND In a randomized phase III trial, pemetrexed plus cisplatin was associated with improved survival compared with cisplatin alone for patients with malignant pleural mesothelioma (MPM). However, there are limited data available on the efficacy of these and other chemotherapy regimens in

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Malignant mesothelioma is a tumour which is generally resistant to chemotherapy. While the addition of interferon to chemotherapy improves response rates in some other malignancies, such a combination has not been evaluated in the treatment of mesothelioma. OBJECTIVE To assess the

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To assess the tolerance, toxicity, and antitumoral activity of the weekly combination of cisplatin (CDDP) and interferon alfa-2a (IFNalpha2a) in advanced diffuse malignant mesothelioma (DMM). METHODS Twenty-six patients with DMM (23 pleural and three peritoneal), previously untreated, were

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To describe the initial experience at Dana-Farber Cancer Institute/Brigham and Women's Hospital with intensity-modulated radiation therapy (IMRT) as adjuvant therapy after extrapleural pneumonectomy (EPP) and adjuvant chemotherapy. METHODS The medical records of patients treated with IMRT

Malignant peritoneal mesothelioma presenting with persistent high fever.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Malignant peritoneal mesothelioma (MPM) is a rare tumor that develops in the peritoneum. In this paper, we describe an extremely rare case of MPM metastasizing to the appendix in a 48-year-old female who initially presented with a persistent high fever. The woman reported a slight lower abdominal

Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE Management of malignant pleural mesothelioma (MPM) has been an important clinical issue regardless of the treatment modality employed. We aimed to investigate the efficacy of oxytetracycline (OT), Corynebacterium parvum (CP), and nitrogen mustard (NM) in the management of pleural effusion

Approach to offering remote support to mesothelioma patients: the mesothelioma survivor project.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND From the moment of diagnosis, malignant mesothelioma (MM) decreases health-related quality of life (QOL) in patients and their caregivers. In addition to symptoms of disease, aggressive treatments such as surgery, radiation, and chemotherapy can cause extreme side effects-chemotherapy

Tidigare
1
2
3
4
5
6
7
8
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning